Announcement from the nomination committee concerning the Annual General Meeting 2015

Recipharm’s nomination committee proposes that Carlos von Bonhorst be elected as
a new board member. The nomination committee also proposes re‑election of all
board members: Marianne Dicander Alexandersson, Lars Backsell, Anders G.
Carlberg, Thomas Eldered, Göran Pettersson, Tony Sandell and Joan Traynor.
Re-election of Lars Backsell as chairman of the board is furthermore proposed.

Carlos von Bonhorst has held several leading positions in the European
pharmaceuticals industry and as a scientific expert and advisor to boards and
management teams in the field of pharmaceuticals. Carlos von Bonhorst holds a
degree in medicine from the Universidade Clássica de Lisboa (Lisbon), and has
also worked as a physician. He was born in 1957, grew up in Portugal and
currently lives in Brussels, Belgium.

The nomination committee has comprised Per Lundborg, chairman (appointed by B &
E Participation AB), Lars Backsell (chairman of the board of Recipharm), Johan
Lannebo (appointed by Lannebo Fonder) and Frank Larsson (appointed by
Handelsbanken Fonder).

The nomination committee’s other proposals regarding chairs of meetings, fees
and how the nomination committee is to be appointed will be published on the
website and announced in the notice of the AGM.

Recipharm’s Annual General Meeting will be held on 7 May 2015 at 2pm on
Recipharm AB’s premises at Lagervägen 7, 136 50 Jordbro, Sweden.

In the event of any questions please contact:
Per Lundborg, chairman of the nomination committee

Mob.: +46 709 68 16 05

or

Lars Backsell, member of the nomination committee
Tel.: +46 8 602 52 00

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry employing some 2,200 employees.
Recipharm offers manufacturing services of pharmaceuticals in various dosage
forms, production of clinical trial material including API and pharmaceutical
product development. Recipharm manufactures more than 400 different products to
customers ranging from Big Pharma to smaller research- and development
companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company
operates development and manufacturing facilities in Sweden, France, the UK,
Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The
Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03
www.recipharm.com